TM plus capecitabine for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a drug called tetrathiomolybdate (TM) combined with capecitabine for people with triple-negative breast cancer who still have cancer cells after standard chemotherapy and surgery. The goal is to see if this combination can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have triple-negative breast cancer (ER-, PR-, HER2-).
- You must have completed at least 6 cycles of standard chemotherapy before surgery.
- After surgery, you must still have some cancer cells found in the breast or lymph nodes.
- You cannot have any signs of cancer on scans or physical exam after surgery.
- You must be in good physical shape (Karnofsky score 90 or 100).
- You cannot have had capecitabine before, and you cannot be taking warfarin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at different ways to use the chemotherapy drug capecitabine for people with triple-negative breast cancer who still have cancer cells after initial treatment and surgery. It aims to find the best approach to improve outcomes.
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.